 Dopamine Agonists
"Dopamine Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate dopamine receptors.
| Descriptor ID |
D018491
|
| MeSH Number(s) |
D27.505.519.625.150.151 D27.505.696.577.150.151
|
| Concept/Terms |
Dopamine Agonists- Dopamine Agonists
- Agonists, Dopamine
- Receptor Agonists, Dopamine
- Dopamine Receptor Agonist
- Agonist, Dopamine Receptor
- Receptor Agonist, Dopamine
- Dopamine Receptor Agonists
- Dopaminergic Agonists
- Agonists, Dopaminergic
- Dopaminergic Agonist
- Agonist, Dopaminergic
- Agonists, Dopamine Receptor
- Dopamine Agonist
- Agonist, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agonists".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agonists".
This graph shows the total number of publications written about "Dopamine Agonists" by people in this website by year, and whether "Dopamine Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 2 | 3 | | 2009 | 0 | 2 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 3 | 3 | | 2014 | 1 | 2 | 3 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 2 | 3 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dopamine Agonists" by people in Profiles.
-
Schamiloglu S, Lewis E, Keeshen CM, Hergarden AC, Bender KJ, Whistler JL. Arrestin-3 Agonism at Dopamine D3 Receptors Defines a Subclass of Second-Generation Antipsychotics That Promotes Drug Tolerance. Biol Psychiatry. 2023 10 01; 94(7):531-542.
-
Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020 12; 21(4):667-678.
-
Framnes-DeBoer SN, Bakke E, Yalamanchili S, Peterson H, Sandoval DA, Seeley RJ, Arble DM. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor. Am J Physiol Endocrinol Metab. 2020 01 01; 318(1):E62-E71.
-
Nevzati E, Chatain GP, Carr SB, Lillehei KO, Kerr JM. Surgical management considerations in cystic prolactinomas-a single center case series. Endocrine. 2020 01; 67(1):58-66.
-
Larson TA, Winkler MC, Stafford J, Levis SC, O'Neill CE, Bachtell RK. Role of dopamine D2-like receptors and their modulation by adenosine receptor stimulation in the reinstatement of methamphetamine seeking. Psychopharmacology (Berl). 2019 Apr; 236(4):1207-1218.
-
Schacht JP, Voronin KE, Randall PK, Anton RF. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. Neuropsychopharmacology. 2018 05; 43(6):1247-1256.
-
Frank GK, Shott ME, Hagman JO, Schiel MA, DeGuzman MC, Rossi B. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. Int J Eat Disord. 2017 Apr; 50(4):447-450.
-
Akturk HK, Nippoldt TB. Low Testosterone in Men Should Be a Sign Rather Than a Number to Increase: A Teachable Moment. JAMA Intern Med. 2016 12 01; 176(12):1743-1744.
-
Schacht JP. COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review. Pharmacogenomics J. 2016 10; 16(5):430-8.
-
Garcia-Borreguero D, Silber MH, Winkelman JW, H?gl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016 05; 21:1-11.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|